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Studies of human papillomaviruses (HPVs) are hampered by the lack of a conventional culture system because HPV
completes its life cycle only in fully differentiated human tissue. To overcome this obstacle, the athymic mouse xenograft
system has been used to study the pathogenesis of HPV 11 and to develop neutralizing assays for vaccine development.
Recently, HPV 40 has been produced in this system, and HPV 16 has been produced using mice with severe combined
immune deficiency. To identify and characterize additional genital HPV types for similar studies, condylomata acuminata
lesions containing a high copy number of HPV and detectable L1 major capsid protein were used to prepare infectious virus
stocks. Human foreskin fragments were infected with the virus preparations and implanted under the renal capsules of
athymic mice. After 5 months of growth, implant tissue was removed and processed for studies to detect HPV infection.
Evidence of HPV infection was noted in some of the implants, but in contrast to HPV 11-infected epithelium, the implants
derived from the new virus preparations contained a lesser degree of acanthosis, less developed koilocytosis, and a reduced
number of preserved nuclei in the hyperkeratotic material within the cyst lining. The L1 consensus region was amplified by
polymerase chain reaction from implant DNA and sequenced. Alignment of the amplified sequences with those in the HPV
sequence database showed that the 452-bp amplimer was closely related but not identical to HPV LVX82 and HPV MM7 (also
called Pap 291). The entire 7.9-kb genome was amplified by polymerase chain reaction and cloned. The presence of virions
of the new isolate (named HPV IU) in the implants was verified by immunohistochemical detection of L1 major capsid protein
and by demonstration of virion particles by electron microscopy. A second extract was made from one of the new implants
and used to successfully propagate HPV IU. These experiments demonstrate that experimental infection of human epithelium
with the new isolate, HPV IU, is associated with histological abnormalities that differ in potentially important ways from the
changes observed in experimental HPV 11 infection. © 1998 Academic Press
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INTRODUCTION
Genital tract infections with human papillomaviruses
(HPVs) are manifested in many ways, from an asymp-
tomatic carrier state, to the commonly recognized dis-
ease condylomata acuminata (genital warts), and to
overt malignancy. Approximately half of the 90 known
HPV types infect the genital tract. Infections with certain
genital HPVs, such as HPV types 6 and 11, cause exter-
nal genital warts, a condition characterized by marked
epithelial proliferation and a low risk of dysplastic
changes (zur Hausen and de Villiers, 1994). In contrast,
other genital HPVs, including types 16, 18, and 31, are
highly associated with dysplastic cervical lesions (zur
Hausen and Rosl, 1994; zur Hausen, 1996). These dys-
plasia-associated, or “high-risk,” HPV types can be de-
tected in external genital warts removed from immuno-
suppressed patients (Brown et al., 1994a). About half of
the lesions from immunosuppressed patients contain a
high-risk HPV type, often in a mixed infection with a
“low-risk” type such as HPV type 6 or 11. Such mixed
infections are less common in persons with normal im-
munity (Brown et al., 1994a). In addition, lesions removed
from immunosuppressed or pregnant patients often con-
tain larger quantities of HPV DNA and viral capsid pro-
tein (L1 protein) than lesions removed from other pa-
tients (Brown et al. 1994a,1992, 1993b).
For an HPV to be assigned a type number, the entire
genome must be cloned, and three gene regions (E6, E7,
and L1) must be sequenced and compared with known
types (Van Ranst et al., 1993). With the advent of consen-
sus primer polymerase chain reaction (PCR) amplifica-
tion for detection of HPV DNA in clinical specimens
(Manos et al., 1989), it has become clear that there are a
significant number of HPVs in addition to the numbered
types. The most commonly used consensus PCR system
uses degenerate primers located in a conserved region
of the L1 (major capsid) gene to amplify a segment of1 To whom reprint requests should be addressed.
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;450 bp. A number of HPV sequences have been found
that do not match well with any of the known (numbered)
HPV types (Bernard et al., 1994). These are usually des-
ignated by an arbitrary name assigned by the group that
first recognized it. In some cases, the same or closely
related sequences are independently reported by differ-
ent groups and given different names. Although these
almost certainly represent novel HPV types, they are
designated by these “unconventional” names until the full
genome is cloned and characterized. The true preva-
lence, clinical manifestations, and clinical importance of
these partially characterized HPVs are not known. Sev-
eral of the uncharacterized HPVs have been identified in
specimens from immunocompromised patients (Shah et
al., 1997).
To identify and characterize additional genital HPV
types for studies of HPV pathogenesis, an extract was
prepared from genital lesions removed from immunosup-
pressed patients, pregnant women, and patients with
large lesions containing L1 protein. Preparing a pooled
extract from these biopsies was done to increase the
changes of inducing an infection in the foreskin tissue
with any HPV present in abundance. This extract was
used to infect human foreskin fragments, which were
implanted under the renal capsules of athymic mice as
described by Kreider et al. (1987, 1986). The resulting
implants were analyzed for HPV infection, and a second
extract was prepared from implants containing evidence
of HPV infection for use in propagation experiments. An
HPV closely resembling HPV MM7/LVX82 (also known
as Pap 291) was identified in the original implants, and
propagation in the athymic mouse xenograft system
proved successful. We refer to this new isolate as HPV IU
in this report.
RESULTS
Gross and microscopic characterization
of HPV-infected implants
In an effort to propagate additional HPV types, an
extract was made from 33 lesions known to contain large
quantities of HPV DNA and HPV L1 capsid protein. Hy-
brid capture analysis of the high speed pellet and the
banded virus preparation showed that abundant viral
DNA was present for the A and B probe groups. Probe
group A contained the low-risk HPV types 6, 11, 42, 43,
and 44, whereas probe group B contained the high-risk
HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 56. Each of
these preparations were used to infect human foreskin
fragments, which were then implanted into athymic mice.
Mice were sacrificed 150 days after implantation of fore-
skin tissue, and implants were removed from the mice.
Four implants from the first experiment, two using the
high speed pellet and two using banded virus, appeared
much larger with a rougher texture than the other 12
implants. The larger tumors appeared to adhere to the
kidney surface and extend outward, clearly demarcated
from the mouse kidney tissue (Fig. 1). When cut trans-
versely, the implants were thin walled and contained
solid, dry cellular debris.
Uninfected and HPV 11-infected implants grown in
athymic mice were used as controls for comparison of
histology. In the uninfected control implants grown for
150 days, the epithelial tissue consisted of a single basal
layer with four to six additional layers of flattened inter-
mediate squamous cells and a thin granular layer. Cel-
lular debris and keratinized material was present in the
center of the implant (Figs. 2A and 2B). No nuclei were
present in the material in the center of the implant. In
contrast, the HPV 11-infected implant demonstrated
marked epithelial thickening (acanthosis). The parabasal
layer was expanded and involved approximately one
third of the epithelium (Figs. 2C and 2D). Papillomatosis
(papillary projections of the epidermis forming a micro-
scopically undulating surface) was present, with invagi-
nation from the underlying stroma by fibrovascular sup-
ports. The suprabasal layer of the HPV 11-infected im-
plant contained well developed koilocytes containing
nuclei that were enlarged two to three times compared
with nuclei of suprabasal cells in uninfected implants.
Marked parakeratosis (retention of nuclei in cells of the
FIG. 1. An HPV IU implant removed from an athymic mouse. A mouse
kidney is shown with a large tumor under the renal capsule (arrows).
The spaces between the measurement bars represent 2-mm intervals.
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stratum corneum) was observed, as well as accumula-
tion of cellular debris and hyperkeratotic material within
the implant. In addition, nuclei were present in abun-
dance in the shed material in the center of the implant.
In implants infected with HPV IU, there were areas of
mild parabasal hyperplasia with increased mitotic activ-
ity (Figs. 2E, 2F, 3A, and 3B). Although epithelial thicken-
ing was noted compared with the uninfected implant,
HPV IU implants were significantly less acanthotic than
the HPV 11 implant after the same 150 days of growth
(Figs. 2E, 2F, and 3A). In addition, hypergranulosis (an
abundance of granular cytoplasmic structures) and mild
parakeratosis were present. Similar to the HPV 11-in-
fected implant, the epithelium was abnormal throughout,
with marked nuclear enlargement in the suprabasal and
subcorneal zones. Nuclei were at least three times en-
larged compared with normal suprabasal cell nuclei.
Koilocytotic vacuole development was present although
not nearly as flagrant as was seen in the HPV 11-infected
implant. For subcorneal cells, a higher nuclear-to-cyto-
plasmic ratio was observed in the HPV IU-infected im-
plant compared with the HPV 11-infected implant. Basal
cell crowding was seen, occasionally very focal in nature
(Fig. 3B). In addition, parakeratosis was observed, as
well as accumulation of cellular debris and hyperkera-
totic material within the implant. In contrast to the HPV
11-infected implant, very few nuclei were present in the
center of the HPV IU-infected implants.
In summary, the main histological differences between
the implants infected with HPV IU and the HPV 11-
infected implant were (1) a lesser degree of acanthosis
in the implants infected with the new virus preparation,
(2) less developed koilocytosis in the implants infected
with the new virus, and (3) a markedly reduced number of
preserved nuclei present in the hyperkeratotic material
within the implants infected with HPV IU compared with
HPV 11-infected implants.
Expression of HPV capsid antigen and whole virus
Immunohistochemical assays were performed using a
polyclonal antiserum against a bacterially expressed
HPV 11 trpE-L1 fusion. Dark-brown staining of nuclei of
differentiated keratinocytes was seen in implants con-
taining the histological abnormalities described above
(Fig. 4). By analogy with other papillomavirus systems,
FIG. 2. Histology of uninfected and HPV-infected human foreskin implants grown for 150 days in athymic mice. Implants were paraffin embedded, and
sections were stained with hematoxylin and eosin. (A and B) Uninfected implant. (C and D) HPV 11-infected implants. (E and F) HPV IU-infected implant.
Original magnification, 1003 (A, C, and E) or 4003 (B, D, and F). The arrows in A, C, and E indicate the basal cell layer, and arrowheads indicate the corneal
cell layer. Material at the top of each figure is the keratin debris shed into the center of the implant. The circle in D illustrates a nucleus that has been shed
into the keratin and cell debris in the center of the implant. In F, note the absence of nuclei in the shed material within the implant.
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this observation suggests that the most differentiated
cells were making capsid protein and were likely to be
producing virus particles.
Electron microscopy was performed to verify the pro-
duction of virions. Electron micrographs revealed abun-
dant particles of ;50 nm in the nuclei of numerous
FIG. 3. Histology of two additional HPV IU-infected human foreskin implants grown for 150 days in athymic mice (hematoxylin and eosin stain).
(a and b) The two implants. The arrows in both panels indicate the basal cell layer, and arrowheads indicate the corneal cell layer. Note the mild
epithelial thickening in a, and the focal basal cell crowding in b. Original magnification, 2003.
FIG. 4. Immunohistochemistry for detection of L1 major capsid protein in HPV IU-infected human foreskin implants grown in athymic mice. The
arrow illustrates the position of the basal cell layer, and arrowheads indicate the corneal cell layer. Original magnification, 4003.
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differentiated cells (Fig. 5). These particles resembled
typical icosahedral papillomavirus. Both apparently full
(appearing dense and dark) and empty (appearing less
dense) capsids were observed.
Detection and characterization of HPV IU DNA
Hybrid capture analysis was performed as a screen for
common genital HPV types on DNA purified from HPV
IU-infected implants with abnormal histology. These
studies were negative with both the A and B probe
groups, indicating that a common genital HPV type was
not present in the new implants.
Southern blot analysis was performed at low strin-
gency using a mixture of HPV types 6b, 11, 16, and 18
genomic DNAs as probes. The low stringency Southern
blot analysis of PstI-digested DNA from implants infected
with HPV IU showed faint bands of ;2900, ;1600,
;1200, ;900, and ;800 bp after exposure of the auto-
radiogram for 7 days (Fig. 6). As controls, a high copy
number sample containing HPV 6c and a low copy num-
ber condylomata acuminata lesion containing HPV 16
were included in the blot (Fig. 6). The faint bands seen in
the 7-day exposure did not correlate with any PstI re-
striction patterns for HPV types commonly associated
with genital warts.
L1 consensus primers were used to amplify HPV se-
quences from the new implants, and the amplimers were
cloned and sequenced. Alignment of the amplified se-
quences with those in the HPV sequence database
showed that the 452-bp PCR product was nearly identi-
cal to HPV LVX82 (Ong et al., 1994) and HPV MM7 (also
called Pap 291) (Manos et al., 1994), two uncharacterized
(and unnumbered) HPVs. Eight independent clones from
both initial and passaged implants were sequenced and
were identical to each other. All eight differed at four
positions (outside of the degenerate primer region) from
the HPV LVX82 sequence and at six positions from the
HPV MM7 sequence. However, translation of all three
sequences yielded an identical 150-amino-acid se-
quence (with the exception of one change encoded in
the primer region). It is therefore likely that HPV LVX82,
HPV MM7, and the new isolate, HPV IU, represent se-
quence variants of a single yet unnumbered HPV type.
FIG. 6. (Left) Low stringency Southern blot (1.2% agarose gel) of DNA
extracted from condyloma acuminata lesions and implants tissue in-
fected with HPV IU and digested with PstI. The probes used were a
mixture of HPV types 6b, 11, 16, and 18. Lane 1, HPV 6c-containing
condyloma acuminata lesion. Lane 2, HPV 16-containing lesion. Lane 3,
HPV IU-infected implant grown in an athymic mouse. Arrowheads on
the left side of lane 3 indicate the faint bands visualized after 7 days of
exposure. (Right) High stringency Southern blot (1.2% agarose gel) of
DNA extracted from HPV IU-infected implant tissue. The probe used in
the high stringency blot was PCR-amplified HPV IU DNA. Lane 1, PstI
digest. Lane 2, BamHI digest. Lane 3, HincII digest. Lane 4, EcoRI
digest. Lane 5, no restriction endonuclease added. Molecular markers
in kb are shown on the left side of each blot.
FIG. 5. Electron micrographs of HPV IU-infected human foreskin
implants grown in athymic mice. The measurement bar is ;100 nm at
the plane of the photograph. Original magnification, 90,0003.
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Using PCR primers extending outward from the L1
consensus primer region, the entire 7.9-kb genome of
HPV IU was amplified and cloned. The full-length DNA
was then used as a probe for high stringency Southern
blotting (Fig. 6). A similar PstI pattern was visualized in
the high stringency blot as was seen on the low strin-
gency blot, with an obvious doublet present of ;800 and
;900 bp. The sum of PstI restriction fragments was very
close to 7900 bp, with bands corresponding to approxi-
mately ;2900, ;1600, ;1200, ;900, ;800, and ;500
bp. Digestion with BamHI resulted in a single band at 7.9
kb (Fig. 6). Digestion with HincII resulted in a dark, wide
band at ;4 kb, suggesting that two bands of nearly equal
size were generated from episomal HPV DNA. This indi-
cated the presence of two HincII sites in the HPV IU
genome. EcoRI digestion resulted in a high-molecular-
weight band similar to the band present when no endo-
nuclease was added, suggesting that no EcoRI site was
present.
To demonstrate the presence of HPV IU DNA and to
exclude the presence of other common genital HPV
types, implants were analyzed by DNA in situ hybridiza-
tion using the whole genomic HPV IU probe or one of
three probe mixes consisting of HPV types 6 and 11, HPV
types 16 and 18, and HPV types 31, 33, and 51. Only
hybridization with the HPV IU probe resulted in positive
signals (Fig. 7). No positive signals were present in
sections hybridized with the other HPV probe groups,
suggesting an absence of these other HPV types in the
new implants (data not shown).
Propagation of HPV IU
To verify that HPV IU could be propagated in the
athymic mouse xenograft system, an extract was made
from an implant from the initial experiment and used to
infect a second human foreskin. Fragments of this fore-
skin were implanted into 16 athymic mice. Mice were
sacrificed after 150 days of growth, and implants were
removed. Of the 32 passaged implants, 20 were signifi-
cantly larger than the remaining implants and had the
same outward extension and demarcation from kidney
tissue as appeared in the HPV IU-infected implants from
the initial experiment. The remaining 12 implants were
spherical and smooth, with the typical appearance of
uninfected foreskin implants. Histological analysis of
these larger passaged implants was similar to that of the
original group of HPV IU implants. Histological analysis
of the smaller implants resembled that of uninfected
implants grown in athymic mice. As described above, the
DNA sequences of the 452-bp amplimers from pas-
saged, HPV IU-infected implants were identical to those
from the original implants.
DISCUSSION
In this report, we describe the preparation of an infec-
tious stock of HPV IU, a genital HPV related to HPV
FIG. 7. DNA in situ assay of HPV IU-infected human foreskin implants grown in athymic mice. The arrow illustrates the position of the bsal cell layer,
and arrowheads indicate the corneal cell layer. The probe was PCR-amplified HPV IU DNA. Similar sections probed with DNA from HPV types 6, 11,
16, 18, 31, 35, and 51 showed no reaction (not shown). Original magnification, 4003.
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MM7/LVX82. Although epidemiological studies of HPV
MM7/LVX82 are limited, the available data support a
hypothesis that infection with this type is relatively com-
mon compared with other genital HPVs. All published
studies that have identified HPV MM7/LVX82 have been
performed on cervical lavage or cervical biopsy samples
rather than in DNA extracted from genital warts. In one
study, HPV MM7/LVX82 was identified in 20 of 338, or
5.9%, of cervical samples from patients with low grade
dysplasia, and 1 of 43, or 2.3%, of high grade dysplasia
samples. In a study of cervical HPV acquisition by col-
lege women, incident infection with HPV MM7/LVX82
(called Pap 291 in this study) was identified in 15 of 529,
or 2.8%, of women followed over a period of 2 years,
making it one of the more common types acquired (Ho et
al., 1998).
In another study, Shah et al. (1997) identified 22 HPV
types in cervical lavage samples of human immunodefi-
ciency virus (HIV)-seropositive women and seven types
in lavage samples from HIV-seronegative women. Over-
all, 104 of 150, or 69.3%, of HIV-seropositive women had
detectable HPV compared with 19 of 72, or 26.4%, of
HIV-seronegative women. The most prevalent HPV type
detected in both groups of women was HPV MM7/LVX82,
accounting for 20 of 150, or 13.3%, of HPV-seropositive
women and 5 of 72, or 6.9%, of HIV-seronegative women.
Of the 123 women with detectable HPV of any type, HPV
MM7/LVX82 was the most common type detected,
present in 20% of samples. The next most commonly
detected types were HPV 52 (12 of 123 HPV-positive
women, or 9.8%), HPV 54 (11 of 123, or 8.9%), and HPV 18
(10 of 123. or 8.1%). The prototype genital HPV considered
to be low risk (HPV 6) was detected in 4 of 123, or 3.3%,
of HPV-positive women. HPV 16, the prototype high risk
genital type, was detected in 9 of 123, or 7.3%, of HPV-
positive women. Abnormal cervical cytology was highly
correlated with HIV seropositivity and degree of immu-
nosuppression. No specific data were given for associ-
ation of HPV MM7/LVX82 with dysplasia in either HIV-
seropositive or -seronegative women.
Recently, Christensen et al. (1997) reported the prop-
agation of HPV 40 and an isolate consistent with HPV
MM7/LVX82 as a mixed infection in the athymic mouse
xenograft system. The source of infectious virus was
from an anal condyloma acuminata lesion removed from
a female renal transplant recipient. The two virus types
were detected by DNA in situ hybridization in distinctly
separate areas of the epithelial implant. An infectious
stock of HPV MM7/LVX82 was not obtained, possibly
because implants contained very little HPV MM7/LVX82
compared with HPV 40. Interestingly, PCR with consen-
sus L1 primers preferentially amplified the less abundant
HPV MM7/LVX82 in the anal lesion removed from the
patient despite the predominance of HPV 40 DNA.
Because there were HPV types other than HPV IU
detected by hybrid capture in the inoculum used in our
study, we were concerned that other types could be
present in the new implants. Our experimental data sug-
gested that this was not the case. First, a total of eight
implants were examined by PCR and subsequently se-
quenced; all amplimers contained the identical HPV IU
sequence. Second, the low stringency Southern blot us-
ing probes of HPV types 6, 11, 16, and 18 yielded bands
adding up to ;7900 bp. These bands did not match the
PstI pattern of any common genital HPV type. Third, the
high stringency Southern blot using the HPV IU whole
genomic probe yielded a PstI restriction pattern identical
to that of the low stringency blot. Fourth, the DNA in situ
assay was negative for HPV types 6, 11, 16, 18, 31, 33, and
35. Finally, the hybrid capture assay was negative for the
14 types commonly found in genital tract infection. These
studies therefore suggest that significant amounts of
other HPV types were not present in the HPV IU-infected
implants. We cannot completely rule out contamination
with very small quantities of other HPV types.
Because HPV MM7/LVX82 appears to be a relatively
common genital type, at least in HIV-infected women, the
number of cases of cervical abnormalities caused by this
type may be relatively large. A feasible method of reduc-
ing the incidence of genital tract HPV infection is the
development of effective vaccines. Several studies sug-
gest that type-specific vaccines will be required to pro-
tect against the many HPVs known to exist (Christensen
et al., 1994; Rose et al., 1994; Hines et al., 1994; Ludmerer
et al., 1996; Roden et al., 1996). To accomplish this goal,
it will be necessary to identify, sequence, and establish
neutralization assays for prevalent genital HPV types.
Recently identified and uncharacterized HPVs such as
HPV MM7/LVX82 should not necessarily be considered
rare or medically unimportant. In addition to the well
characterized genital HPVs such as HPV types 6 and 16,
many of these newly identified types may also need to be
included in effective vaccines. More extensive knowl-
edge of HPV MM7/LVX82 epidemiology is needed to
determine whether a vaccine would have an impact on
reducing the prevalence of cervical dysplasia or genital
warts in immunosuppressed and otherwise healthy
women.
HPV IU induces changes in human epithelium grown
as implants in athymic mice that differ from those ob-
served in experimental HPV 11 infection. Experimental
HPV 11 infection is histologically identical to condylo-
mata acuminata (genital warts), but it has not been
proved that experimental HPV IU infection is identical to
natural infection of genital tissue. We are currently ex-
amining patient biopsies for evidence of HPV IU infection
by PCR and by examining sections for histological
changes suggesting infection with this virus. These stud-
ies will be the subject of a later report. HPV IU-infected
implants differ from HPV 11-infected implants in several
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ways. In comparison with HPV 11-infected implants, the
HPV IU-infected implants exhibit a milder degree of ep-
ithelial proliferation, less pronounced koilocytosis, and a
near absence of preserved nuclei in the cellular debris
and keratinized material within the cyst. These findings
suggest that natural HPV IU infection differs in important
ways from infection with HPV 11. Exploration of the dif-
ferences between the changes induced by these viruses
could further the understanding of HPV pathogenesis.
MATERIALS AND METHODS
Preparation of virus extract from tissue
Thirty-three excision biopsies of exophytic condylo-
mata acuminata lesions were performed as previously
described (Brown et al., 1994a). All of the biopsy samples
were analyzed by Southern blot analysis of hybrid cap-
ture for detection of HPV DNA (Brown et al., 1993a).
Twenty-seven of the lesions were removed from patients
with conditions known to be associated with defects in
cellular immunity. Nine of the lesions were removed from
patients who were iatrogenically immunosuppressed af-
ter transplantation of kidney or liver; seven were re-
moved from patients infected with HIV; and 11 were from
pregnant women. The remaining six patients were not
immunosuppressed or pregnant but had unusually large
genital lesions, thus providing abundant infected tissue.
Lesions from these 33 patients were combined in a
large polypropylene tube with 100 ml of solution 1 [50
mM NaPO4 (di/mono), pH 8.0, 200 mM NaCl, 10 mM
EDTA] prechilled to 4°C. Using a Biosonik IV tissue
homogenizer (Bronwill, Rochester, New York) on the low-
est setting, the tumor tissue was homogenized to a thick
suspension, and the extract was chilled on ice. The
tissue extract was centrifuged for 5 min at 5000 g at 4°C.
The supernatant was collected and stored on ice. An
additional 50 ml of solution 1 was added to the pellet,
and ultracentrifugation was repeated as above. The two
low speed supernatants were combined and diluted with
an additional 50 ml of solution 1, and ultracentrifuged at
20,000 g at 4°C for 2 h to pellet HPV. The supernatant
was discarded, and the resulting high speed pellet was
suspended in 5 ml of solution 2 [50 mM NaPO4 (di/
mono), pH 7.4, 10 mM NaCl, 10 mM EDTA].
Half of this suspension derived from the high speed
pellet was reserved (“high speed pellet”), and to the other
half, CsCl was added to a density of 1.34 g/ml. Centrifu-
gation was performed at 50,000 g at 20°C for 18 h. A faint
band was visualized by shining a small light up through
the bottom of the tube. This band was removed using an
18-gauge needle. Additional solution 2 plus CsCl was
added to a density of 1.34 g/ml, and centrifugation was
repeated. A visible band was removed and dialysis was
performed against three changes of phosphate-buffered
saline, pH 7.4, and the resulting banded virus preparation
was stored at 70°C.
Infection and implantation of tissue into athymic mice
Infection of human foreskin fragments and growth in
athymic mice were performed as described originally by
Kreider et al. (1987, 1986) with slight modifications as
previously described (Brown et al., 1995). Experiments
were performed using the two preparations described
above (high speed pellet suspension and banded virus),
using eight athymic mice for each virus preparation.
Additional experiments were performed using extracts
from tumors resulting from the first experiments to dem-
onstrate propagation of virus in the athymic mouse xeno-
graft system. Mice were sacrificed 150 days after implan-
tation of foreskin fragments.
Light microscopy, immunohistochemistry, and
electron microscopy
A portion of each implant was placed in zinc Formalin,
and paraffin-embedded sections were prepared. One
section was stained with hematoxylin and eosin. Histo-
logical evaluation of sections was performed, using un-
infected implant tissue and HPV 11-infected human fore-
skin implants grown in athymic mice for 150 days for
comparison (Brown et al., 1994b). Additional sections
were deparaffinized and used to detect L1 protein with a
rabbit polyclonal antiserum raised against a bacterially
expressed HPV 11 trpE/L1 fusion protein, as previously
described (Brown et al., 1994b). This antiserum has been
shown in our laboratory to react with L1 protein from
several HPV types (unpublished data). Preimmune rabbit
serum was used as control serum. Antibody binding was
detected using the Vectastain ABC Kit (Novocastra, New-
castle upon Tyne, UK). Positive cells for L1 protein were
identified by brown staining of nuclei in differentiated
keratinocytes. For electron microscopy, a portion of an
implant was fixed in 3% glutaraldehyde, and the tissue
was embedded and sectioned. Sections were stained
with uranyl acetate.
Hybrid capture assay and Southern blots
DNA was extracted from implants as previously de-
scribed (Brown et al., 1993a). The hybrid capture assay,
marketed as ViraType Plus (Digene Diagnostics, Belts-
ville, Maryland) was used to detect HPV sequences in
the implants (Brown et al., 1993a). HPV probes were used
in two pools whose composition was based on the as-
sociation of each type with genital tract malignancy.
Probe group A contained the “low-risk” HPV types 6, 11,
42, 43, and 44, whereas probe group B contained the
“high-risk” HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 56.
For Southern blots, genomic DNA from an implant that
contained histological features of HPV infection was di-
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gested with one of several restriction endonucleases:
PstI, BamHI, HincII, EcoRI, or no added restriction endo-
nuclease. The probes used in the first Southern blot (low
stringency) were a mixture of HPV types 6b, 11, 16, and
18, all cut from pUC 19 and gel purified. Southern blots
were performed as previously described (Brown et al.,
1993a). For the low stringency blot, prehybridization, hy-
bridization, and washes were performed at 55°C. A sec-
ond Southern blot was performed at high stingency con-
ditions (65°C hybridization and wash) using the PCR-
amplified whole genome of the new isolate, HPV IU, as a
probe (see below).
Consensus primer PCR, cloning, and sequencing
PCR was performed using the primer pair My09/
My11 to amplify HPV sequences in genomic DNA
extracted from a total of eight athymic mouse implants
(two from the initial experiments and six from the
propagation experiments) (Manos et al., 1989). A total
of 250 ng of DNA from each implant was used as
template for each of eight individual PCRs. The result-
ing 452-bp) amplimers were cloned into pCR3.1 (In-
Vitrogen, Carlsbad, California) and DNA sequencing
was performed.
Amplification and cloning of the entire HPV IU
genome and DNA in situ assay
To amplify and clone the genome of HPV IU, total DNA
was isolated from an implant containing histological fea-
tures suggesting HPV infection. PCR was performed us-
ing the Extend Long PCR Kit as instructed by the manu-
facturer (Boehringer-Mannheim, Indianapolis, Indiana).
This PCR system uses two polymerases, one without
proofreading (Taq) and one with proofreading (Pwo). The
primer pair was designed using the 452-bp sequence
amplified with L1 consensus primers. The primers were
59-CAG TAG GAT CCT TAT GAT GGC TTG TAT TTT GGG
AGG TTG AT and 39-GCT ATG GAT CCT TTT TAG GGG
CAG GGG CGG AAG GA. Conditions for PCR were 94°C
for 30 s, 66°C for 30 s, and 68°C for 12 min, for a total of
38 cycles. Agarose electrophoresis revealed a band of
;7.9 kbp, which was excised from the gel and purified
with Gene Clean as instructed by the manufacturer (Bio
101, Vista, California).
The 7.9-kb-amplified DNA fragment was cloned into
the Expand Vector 1 (Boehringer-Mannheim) as di-
rected by the manufacturer. This cloning method facil-
itates cloning of large PCR products by size selection
of PCR fragments provided by the lambda packaging
system, eliminating cloning of small DNA fragments.
To prepare a probe for DNA in situ hybridization, the
7.9-kb fragment was removed from the vector by
BamHI endonuclease digestion and gel purification.
Nick translation of the 7.9-kb fragment was performed
with the BioNick kit (Life Technologies, Gaithersburg,
Maryland) to biotinylate the probe. DNA in situ hybrid-
ization was performed using this biotinylated probe
with the PathoGene Kit as directed by the manufac-
turer (Enzo Diagnostics, Farmingdale, New York). Pos-
itive cells were identified by blue staining of nuclei in
differentiated keratinocytes.
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